Acanthoamoeba meningitis treatment
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Here is a comprehensive overview of Acanthamoeba CNS infection (Granulomatous Amebic Encephalitis, GAE) and its treatment:
Acanthamoeba Meningitis / Granulomatous Amebic Encephalitis (GAE)
Background
GAE is caused by at least eight Acanthamoeba species. Unlike Naegleria fowleri (which causes fulminant PAM), Acanthamoeba infection follows a more indolent, subacute course, typically affecting immunocompromised hosts — patients with AIDS, lymphoproliferative disorders, transplant recipients, those on glucocorticoids or chemotherapy, or SLE patients. The organism reaches the CNS hematogenously from a primary focus in the sinuses, skin, or lungs.
Treatment
No established, proven regimen exists. Treatment of free-living amebic CNS infections is largely ineffective with any single agent, and combination therapy is required.
Core Combination Regimen for Acanthamoeba GAE
Several patients have achieved cure or survival with multidrug combinations including various combinations of:
| Drug | Role/Notes |
|---|---|
| Miltefosine | Amebicidal; good CNS penetration; should be included in all combination regimens |
| Voriconazole | Good CNS/CSF penetration; active against Acanthamoeba (note: not active against Balamuthia) |
| Pentamidine isethionate | Part of combination regimens |
| Sulfadiazine | Part of combination regimens |
| TMP-SMX (trimethoprim-sulfamethoxazole) | Part of combination regimens |
| Flucytosine | Part of combination regimens |
| Fluconazole or Itraconazole | Antifungal agents with some activity |
| Azithromycin | May have adjunctive value |
| Amikacin | Included in some successful regimens |
Key principle: Miltefosine should be included in combination therapy for Acanthamoeba CNS infection due to its amebicidal activity and CNS penetration. Voriconazole is also attractive for the same reasons, and both may form the basis of an optimal regimen.
For Cutaneous Lesions (without CNS involvement)
- Topical chlorhexidine gluconate
- Topical ketoconazole
Prognosis
- In AIDS patients and transplant recipients, the course may be accelerated (survival only 3–40 days) because of impaired granuloma formation.
- Early diagnosis and prompt combination therapy are critical for any chance of survival.
Practical Notes
- Miltefosine (brand: Impavido) is commercially available in the US; the CDC no longer provides it directly.
- The most current treatment guidance is available via the CDC (www.cdc.gov/parasites/acanthamoeba) or by contacting CDC at 770-488-7100.
- CSF typically shows lymphocytic pleocytosis, elevated protein, normal or low glucose, with no organisms visible on routine exam.
- CT/MRI may show ring-enhancing lesions mimicking toxoplasmosis, abscess, or neurocysticercosis.
- PCR from CSF or biopsy tissue (available through CDC) is the most sensitive diagnostic method.
Sources: Harrison's Principles of Internal Medicine 22E, p. 1802 | Red Book 2021, p. 359 | Medical Microbiology 9e
This is a shared conversation. Sign in to Orris to start your own chat.